Abstract
Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1s ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.
Keywords: extracellular matrix (ECM), matrix metalloproteinases, Experimental Crescentic Glomerulonephritis, unilateral ureteral obstruction, transforming growth factor beta
Current Drug Targets
Title: PAI-1 as a Target in Kidney Disease
Volume: 8 Issue: 9
Author(s): Yufeng Huang and Nancy A. Noble
Affiliation:
Keywords: extracellular matrix (ECM), matrix metalloproteinases, Experimental Crescentic Glomerulonephritis, unilateral ureteral obstruction, transforming growth factor beta
Abstract: Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1s ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.
Export Options
About this article
Cite this article as:
Huang Yufeng and Noble A. Nancy, PAI-1 as a Target in Kidney Disease, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662373
DOI https://dx.doi.org/10.2174/138945007781662373 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and
Anti-ETAR, on Kidney Transplant Outcome
Current Protein & Peptide Science Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design The Evidence Base for Revascularisation of Chronic Total Occlusions
Current Cardiology Reviews Patent Annotations
Recent Patents on Cardiovascular Drug Discovery High Density Lipoprotein Administration: A New Therapeutic Modality for the Treatment of Cardiovascular Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach
Recent Patents on Cardiovascular Drug Discovery Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Isoflurane Preconditioning Protects the Myocardium Against Ischemia and Reperfusion Injury by Upregulating GRM1 Expression
Current Neurovascular Research Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy The Link between Exercise and Homocysteine in the Alzheimer’s Disease: A Bioinformatic Network Model
CNS & Neurological Disorders - Drug Targets